Buprenorphine medications contain one or two active ingredients plus a set of inactive ingredients that vary by product form. The active ingredient in all versions is buprenorphine hydrochloride, a semi-synthetic opioid derived from thebaine. Many formulations also include naloxone as a second active ingredient to discourage misuse. Beyond that, the inactive ingredients differ significantly depending on whether you’re taking a sublingual tablet, a dissolving film, a skin patch, or an injection.
The Active Ingredient: Buprenorphine Hydrochloride
Buprenorphine hydrochloride has the molecular formula C₂₉H₄₁NO₄·HCl and a molecular weight of 504.10 g/mol. It’s classified as a partial agonist at the brain’s mu-opioid receptors, meaning it activates those receptors but only to a limited degree compared to full opioids like morphine or heroin. It also blocks kappa-opioid receptors. This dual action is what makes it effective for treating opioid use disorder and chronic pain: it reduces cravings and withdrawal symptoms without producing the same intensity of euphoria that full opioids do. As an analgesic, buprenorphine is roughly 25 to 40 times more potent than morphine by weight.
Naloxone in Combination Products
Most buprenorphine products prescribed for opioid use disorder combine buprenorphine with naloxone in a fixed 4:1 ratio. For example, Suboxone sublingual film comes in strengths of 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg (buprenorphine/naloxone). Zubsolv sublingual tablets use slightly different absolute amounts but maintain a similar ratio.
Naloxone is an opioid antagonist, meaning it blocks opioid receptors entirely. When the medication is taken as directed under the tongue, naloxone is poorly absorbed and has little effect. But if someone were to dissolve and inject the tablet or film, the naloxone would become fully active and trigger withdrawal symptoms. This design is a deliberate abuse deterrent built into the formulation itself.
Products used solely for pain management, like Belbuca buccal film and Butrans patches, contain only buprenorphine without naloxone.
Sublingual Tablet Ingredients
Generic buprenorphine sublingual tablets (originally branded as Subutex) contain the following inactive ingredients: lactose monohydrate, mannitol, corn starch, povidone, anhydrous citric acid, sodium citrate, butylated hydroxyanisole, pregelatinized starch, and magnesium stearate.
Each of these serves a specific manufacturing purpose. Lactose monohydrate and mannitol are fillers that give the tablet its bulk and help it dissolve properly under the tongue. Corn starch and pregelatinized starch help the tablet break apart when it contacts saliva. Povidone acts as a binder to hold everything together in solid form. Citric acid and sodium citrate work as a buffer pair to maintain the right acidity level, which affects how efficiently buprenorphine absorbs through the tissue under your tongue. Magnesium stearate prevents the powder from sticking to manufacturing equipment. Butylated hydroxyanisole is an antioxidant that keeps the active ingredient from degrading over time.
If you have lactose intolerance or a dairy allergy, it’s worth noting that these tablets do contain lactose monohydrate. The amount is small, but it’s present in every dose.
Suboxone Film Ingredients
Suboxone sublingual film has a notably different inactive ingredient list: polyethylene oxide, hydroxypropyl methylcellulose, maltitol, acesulfame potassium, lime flavor, citric acid, sodium citrate, FD&C yellow #6, and white ink.
Polyethylene oxide and hydroxypropyl methylcellulose are the film-forming polymers that create the thin, dissolvable strip. Maltitol is a sugar alcohol that adds mild sweetness, while acesulfame potassium is an artificial sweetener. Combined with the lime flavor, these make the film more palatable during the several minutes it takes to dissolve. Citric acid and sodium citrate again serve as pH buffers. FD&C yellow #6 is a synthetic dye, and the white ink is used for printing product identification on the film. Unlike the sublingual tablets, Suboxone film does not contain lactose.
Belbuca Buccal Film Ingredients
Belbuca, used for chronic pain rather than opioid use disorder, is a buccal film placed against the inside of the cheek. Its inactive ingredient list is considerably longer than the other formulations. It includes multiple cellulose-based polymers (carboxymethylcellulose sodium, hydroxyethylcellulose, and hydroxypropylcellulose) along with polycarbophil, which helps the film adhere to the moist tissue inside your cheek.
Belbuca also contains citric acid and monobasic sodium phosphate as buffering agents, propylene glycol as a solvent, saccharin sodium and peppermint oil for taste, vitamin E acetate as a stabilizer, titanium dioxide and yellow iron oxide as colorants, and methylparaben and propylparaben as preservatives. Sodium benzoate and sodium hydroxide round out the formulation. The black identification printing uses shellac and black iron oxide.
The paraben preservatives in Belbuca are worth flagging if you have a known sensitivity, as they can occasionally cause contact reactions in the mouth for some people.
Butrans Transdermal Patch Layers
The Butrans patch, another pain management product, takes a completely different approach. Rather than dissolving in the mouth, it delivers buprenorphine through the skin over seven days. The patch is a layered system with five distinct components: a beige-colored web backing on the outside, an adhesive rim that holds the patch to your skin (this rim contains no medication), a separating layer, the buprenorphine-containing adhesive matrix where the drug is embedded, and a peel-off release liner that you remove before application.
The adhesive matrix is the critical layer. It holds the buprenorphine in a form that slowly migrates through your skin at a controlled rate. Because the drug delivery mechanism is entirely different from oral formulations, the Butrans patch contains none of the fillers, sweeteners, or buffering agents found in tablets and films.
Injectable Formulations
Two FDA-approved extended-release injectable products, Sublocade and Brixadi, deliver buprenorphine via subcutaneous injection. These are administered by a healthcare provider, typically once monthly. Their ingredient profiles center on the polymer delivery systems that create a slow-release depot under the skin, rather than the fillers and flavoring agents found in oral products. Because you don’t self-administer these, their inactive ingredients are less relevant to day-to-day decisions, but your provider can review the full component list if you have known allergies to specific polymers or solvents.
Why Inactive Ingredients Matter
The inactive ingredients in buprenorphine products aren’t pharmacologically inert for everyone. Lactose in sublingual tablets, parabens in Belbuca, and synthetic dyes like FD&C yellow #6 in Suboxone film are all potential allergens or sensitivities for certain people. If you’ve had reactions to any of these substances in other medications or foods, your prescriber can select a formulation that avoids them. The variety of available delivery formats means there’s usually an alternative that works around a specific ingredient concern.